Clinical Trials
442
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (262 trials with phase data)• Click on a phase to view related trials
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
- Conditions
- Stage II T Lymphoblastic Leukemia/LymphomaStage III T Lymphoblastic Leukemia/LymphomaStage IV T Lymphoblastic Leukemia/LymphomaT Acute Lymphoblastic LeukemiaT Lymphoblastic Lymphoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Bone ScanProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingOther: Questionnaire AdministrationProcedure: Positron Emission TomographyRadiation: Radiation TherapyProcedure: Ultrasound Imaging
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1708
- Registration Number
- NCT07072585
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia
- Interventions
- Other: Best PracticeProcedure: Biospecimen CollectionOther: Electronic Health Record ReviewOther: Xylitol-containing Oral WipeDrug: Placebo Administration
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 556
- Registration Number
- NCT07022678
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
- Conditions
- Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline GliomaChildhood GlioblastomaChildhood Malignant Glioma
- Interventions
- Drug: ATM Kinase Inhibitor AZD1390Procedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingRadiation: Radiation TherapyOther: Survey Administration
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 54
- Registration Number
- NCT06894979
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma
- Conditions
- GanglioneuroblastomaGanglioneuroblastoma, NodularHigh Risk Neuroblastoma
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 84
- Registration Number
- NCT06858501
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
- Conditions
- CIC-Rearranged SarcomaSarcoma With BCOR Genetic AlterationsMetastatic Ewing SarcomaMetastatic High Grade SarcomaMetastatic Undifferentiated Round Cell SarcomaRound Cell Sarcoma With EWSR1-non-ETS FusionMetastatic Undifferentiated Sarcoma, Not Otherwise Specified
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestOther: Fludeoxyglucose F-18Procedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Surgical Procedure
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 437
- Registration Number
- NCT06820957
- Prev
- 1
- 2
- 3
- 4
- 5
- 87
- Next
News
Blinatumomab Combination Therapy Wins Prestigious Trial of the Year Award for Pediatric Leukemia Breakthrough
The Children's Oncology Group AALL1731 trial received the David Sackett Trial of the Year Award for demonstrating that adding blinatumomab to chemotherapy reduces relapse risk by about two-thirds in children with B-cell acute lymphoblastic leukemia.
Racial and Ethnic Disparities Persist in Pediatric Neuroblastoma Survival Despite Clinical Trial Access
Black and Hispanic children with high-risk neuroblastoma experience significantly worse survival outcomes compared to white peers, even when treated in standardized clinical trials, according to new research from UT Southwestern Medical Center.
Blinatumomab Plus Chemotherapy Significantly Improves Survival in Pediatric ALL
A clinical trial demonstrated that adding blinatumomab to chemotherapy significantly improves three-year disease-free survival (DFS) rates in children with standard-risk acute lymphoblastic leukemia (ALL).
Larotrectinib Shows High Efficacy in Pediatric Solid Tumors with NTRK Fusion
Larotrectinib demonstrates high effectiveness in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS) and other solid tumors harboring NTRK gene fusions.
Novel Agents Identified for Osteosarcoma Treatment in Children and Young Adults
The Children's Oncology Group has prioritized several novel agents for osteosarcoma treatment, addressing the lack of progress in outcomes for decades.
Lorlatinib Shows Promise in ALK-Driven Refractory Neuroblastoma with Emerging Resistance Mechanisms Identified
A phase 1 trial of lorlatinib in ALK-driven refractory neuroblastoma demonstrated safety and efficacy across all common ALK mutations, with a recommended pediatric dose of 115 mg/m² daily - approximately twice the adult dose.